NatWest Group’s United Therapeutics UTHR Stock Holding History

NatWest Group’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-4,848	Closed	-$636K	–	329
2015 Q3	$636K	Buy	+4,848	New	+$778K	0.01%	249
2015 Q2	–	Sell	-4,857	Closed	-$838K	–	427
2015 Q1	$838K	Buy	4,857 +177	+4%	+$27K	0.01%	241
2014 Q4	$606	Sell	4,680 -10,821	-70%	-$1.39M	0.01%	287
2014 Q3	$1.99K	Buy	15,501 +6,441	+71%	+$664K	0.02%	187
2014 Q2	$802K	Buy	9,060 +2,950	+48%	+$284K	0.03%	294
2014 Q1	$575K	Sell	6,110 -6,566	-52%	-$672K	0.03%	308
2013 Q4	$1.43M	Sell	12,676 -9,606	-43%	-$866K	0.04%	333
2013 Q3	$1.76M	Buy	22,282 +4,955	+29%	+$362K	0.05%	277
2013 Q2	$1.14M	Buy	+17,327	New	+$1.12M	0.02%	446

Other funds holding UTHR

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

NatWest Group's UTHR Position: Q4 2015 in Review

NatWest Group sold out of United Therapeutics (UTHR) in Q4 2015, closing a stake of 4,848 shares — an estimated $636K sold.

NatWest Group first reported a position in UTHR in Q2 2013 and held it in 9 quarters. The position peaked at $1.76M in Q3 2013. 386 funds tracked by Wall St. Rank hold UTHR as of Q4 2015.

NatWest Group reported no remaining United Therapeutics position as of Q4 2015 after selling out during the quarter.
NatWest Group sold 4,848 United Therapeutics shares in Q4 2015, an estimated $636K.
NatWest Group first reported a position in United Therapeutics in Q2 2013 and held it in 9 quarters.
NatWest Group's United Therapeutics position peaked at $1.76M in Q3 2013.
386 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2015.

Based on NatWest Group's 13F filing for Q4 2015, filed 16 Feb 2016.